Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 4;5(1):010901.
doi: 10.1063/5.0030534. eCollection 2021 Mar.

Toward improved models of human cancer

Bryan E Welm  1 , Christos Vaklavas  2 , Alana L Welm  3
Affiliations

Toward improved models of human cancer

Bryan E Welm et al. APL Bioeng. .

Erratum in

Abstract

Human cancer is a complex and heterogeneous collection of diseases that kills more than 18 million people every year worldwide. Despite advances in detection, diagnosis, and treatments for cancers, new strategies are needed to combat deadly cancers. Models of human cancer continue to evolve for preclinical research and have culminated in patient-derived systems that better represent the diversity and complexity of cancer. Still, no model is perfect. This Perspective attempts to address ways that we can improve the clinical translatability of models used for cancer research, from the point of view of researchers who mainly conduct cancer studies in vivo.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Schematic illustrating multiple platforms available for patient-derived models of cancer. Ex vivo and in vitro models (left side) include organ or tissue slice cultures, three-dimensional (3D) organoids, and two-dimensional (2D) monolayer cultures. In vivo models (right side) include patient-derived xenografts (PDX) in mouse, zebrafish, and chicken egg chorioallantoic membrane (CAM) hosts. Information from these model systems can be interchanged to increase our understanding of human cancer biology, to perform drug screening or testing, and, in some cases, for functional precision oncology to inform patient care.
See this image and copyright information in PMC

References

    1. Thomas R. M. et al., “ Concepts in cancer modeling: A brief history,” Cancer Res. 76(20), 5921–5925 (2016).10.1158/0008-5472.CAN-16-1293 - DOI - PMC - PubMed
    1. Radhakrishnan J. et al., “ Organotypic cancer tissue models for drug screening: 3D constructs, bioprinting and microfluidic chips,” Drug Discovery Today 25(5), 879–890 (2020).10.1016/j.drudis.2020.03.002 - DOI - PubMed
    1. Weaver V. M. et al., “ Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies,” J. Cell Biol. 137(1), 231–245 (1997).10.1083/jcb.137.1.231 - DOI - PMC - PubMed
    1. Pickl M. and Ries C. H., “ Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab,” Oncogene 28(3), 461–468 (2009).10.1038/onc.2008.394 - DOI - PubMed
    1. Choi S. Y. et al., “ Lessons from patient-derived xenografts for better in vitro modeling of human cancer,” Adv. Drug Delivery Rev. 79–80, 222–237 (2014).10.1016/j.addr.2014.09.009 - DOI - PubMed

LinkOut - more resources